{
  "id": 17886976,
  "title": "Nurix Therapeutics CFO Hans van Houte sells $74,474 of stock",
  "url": "https://urgent.news/2026/11/03/nurix-therapeutics-cfo-hans-van-houte-sells-74-474-of-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T01:15:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/nurix-therapeutics-cfo-hans-van-houte-sells-74474-of-stock-93CH-4993331"
  },
  "original_language": "en",
  "account": "Nurix Therapeutics CFO Hans van Houte sold $74,474 worth of the company's stock on October 30, 2026. He traded 2,834 shares at prices ranging from $26.135 to $26.42, with an average price of $26.2791. This sale was to cover tax obligations related to the vesting of restricted stock units. Despite the sales, Nurix shares have gained 104% over the past year, trading at $25.70. The stock is considered undervalued according to InvestingPro analysis. In addition to selling some shares, van Houte bought 10,182 more Nurix Therapeutics common shares on the same day, bringing his total holdings to 47,514 shares. His recent actions follow the company's strong quarterly results, including a net gain of $4.73 per share and $673.1 million in collaboration and license revenue. Analysts have mixed opinions on Nurix's stock, with some raising price targets and others lowering them based on revised estimates.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}